CV_Sciences_logo2021.png
CV Sciences, Inc. Reports First Quarter 2022 Financial Results
16. Mai 2022 09:00 ET | CV Sciences, Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV_Sciences_logo2021.png
CV Sciences, Inc. to Announce First Quarter 2022 Results On May 16, 2022
12. Mai 2022 07:00 ET | CV Sciences, Inc.
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV_Sciences_logo2021.png
CV Sciences, Inc. Reports Fiscal Year-End 2021 Financial Results
31. März 2022 16:05 ET | CV Sciences, Inc.
SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV_Sciences_logo2021.png
CV Sciences, Inc. to Announce Fourth Quarter and Full Year 2021 Results on March 31, 2022
28. März 2022 16:05 ET | CV Sciences, Inc.
SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line of CBD Products
UPDATE -- CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line of CBD Products
11. März 2022 12:59 ET | CV Sciences, Inc.
SAN DIEGO, March 11, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line of CBD Products
CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line of CBD Products
08. März 2022 09:11 ET | CV Sciences, Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
+PlusCBD™ Pain Relief topicals
CV Sciences, Inc. Announces Launch of +PlusCBD™ Pain Relief Topicals
11. Januar 2022 08:00 ET | CV Sciences, Inc.
SAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (“CBD”)...
+PlusCBD™ Products Available at GNC
CV Sciences, Inc. Announces New Distribution Agreement with GNC
05. Januar 2022 08:00 ET | CV Sciences, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB: CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV_Sciences_logo2021.png
CV Sciences, Inc. Appoints Haskell & White LLP as Auditor
30. November 2021 16:30 ET | CV Sciences, Inc.
SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV_Sciences_logo2021.png
CV Sciences, Inc. Announces Convertible Note Financing
15. November 2021 08:25 ET | CV Sciences, Inc.
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...